BioAge
Presence
Acquisition, funding and merger involving BioAge.
- BioAge has just announced a $170 Million fundraising (posted on February 20 2024).
Executives
View the org chart displaying its 19 main executives
Most searched biographies at BioAge
- Kristen Fortney, Chief Executive Officer and Director
- Vijay Pande, Director
- Rekha Hemrajani, Independent Director
Popular executive movements at BioAge
- Michael Davidson has joined the company as Director (posted on April 12 2024).
Create your alert
to follow the executive moves at BioAge.
Biotechnology
BioAge has 2,281 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by BioAge
- BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
- BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
- BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
- BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
- BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
- BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
- BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways at Upcoming International Conferences
- BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer
- BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways at Upcoming International Conferences
- BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer
- View more press releases Close
Social media about BioAge
- BioAge on Wikipedia, Google News & Yahoo Finance
- BioAge on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Kristen Fortney 
